Meningioma Symptoms and Treatment

She went in for a follow-up scan after a minor car accident. No headaches. No neurological symptoms. No reason whatsoever to suspect anything was growing in her head. The radiologist spotted it anyway — a small, well-defined mass sitting quietly on the membrane surrounding her brain.

The diagnosis was meningioma. And the neurosurgeon’s first recommendation surprised her completely: do nothing. Just watch it.

She spent the next several weeks convinced she was being undertreated. How could “watch and wait” be the right answer for a brain tumor? It took time — and a proper explanation — before she understood why that recommendation made complete sense for her specific situation.

Meningioma is the most commonly diagnosed primary brain tumor. It affects hundreds of thousands of people every year. Yet most people know almost nothing about it until a scan puts the word in front of them. This article changes that.

What Is a Meningioma?

Meningiomas develop in the meninges — the three layers of protective membranes that surround the brain and spinal cord. These membranes don’t form part of the brain itself. They cover it, protect it, and separate it from the skull.

This location matters more than most people realize. Meningiomas don’t grow inside brain tissue. They grow on the surface, pressing against the brain from outside. This characteristic makes them fundamentally different from tumors like glioblastoma, which invade brain tissue directly.

Approximately 80% of meningiomas are benign — non-cancerous, slow-growing, and with well-defined borders. Around 15% are atypical, meaning they grow faster and carry a higher recurrence risk after treatment. Roughly 2% to 3% are malignant — aggressive tumors that behave more like cancerous growths and require more intensive treatment.

The World Health Organization classifies meningiomas as Grade 1 (benign), Grade 2 (atypical), or Grade 3 (malignant/anaplastic). The vast majority of diagnosed meningiomas fall into Grade 1.

How Common Is Meningioma?

Meningioma is the single most common primary brain tumor type. It accounts for approximately 37% to 40% of all primary brain tumors diagnosed in the United States each year.

Women develop meningiomas roughly two to three times more often than men. This gender difference is significant and is linked to hormonal factors — particularly estrogen and progesterone receptors found on many meningioma cells. The reason meningiomas occur more frequently in women, especially during and after the reproductive years, is an active area of research.

Meningiomas occur most commonly in adults between 40 and 70 years old. They’re rare in children. The incidence increases steadily with age.

Many meningiomas are discovered incidentally — found during imaging performed for an unrelated reason, exactly like my aunt’s situation. Research suggests that a significant number of people carry small, asymptomatic meningiomas throughout their lives without ever knowing it.

What Causes Meningioma?

No single clear cause explains why meningiomas develop. Several risk factors increase the likelihood.

Radiation exposure is the strongest established risk factor. People who received radiation to the head during childhood — historically used to treat conditions like ringworm of the scalp or childhood leukemia — face significantly elevated meningioma risk decades later. Modern radiation therapy uses far more precise techniques, but past exposure remains a risk factor for older patients.

Hormonal factors explain the strong female predominance. Many meningiomas carry receptors for estrogen and progesterone. Long-term use of oral contraceptives and hormone replacement therapy appears to increase risk modestly, though research findings are not entirely consistent. Meningiomas sometimes grow faster during pregnancy, when hormone levels rise dramatically.

Neurofibromatosis type 2 (NF2) is a genetic condition that strongly predisposes to meningioma development, often causing multiple tumors simultaneously in younger patients. The NF2 gene also shows mutations in many sporadic meningiomas without the inherited condition.

Age consistently correlates with increasing meningioma risk. The mechanisms behind this age-related increase are not fully understood but likely involve accumulated genetic changes in meningeal cells over time.

Head injury was historically suspected as a risk factor. Current evidence suggests that trauma does not directly cause meningioma. However, head injury may lead to imaging that discovers a pre-existing meningioma — explaining the apparent association in older studies.

Symptoms of Meningioma

Meningioma symptoms depend almost entirely on tumor location. A meningioma growing near the motor cortex produces different symptoms than one near the optic nerve or the base of the skull. Many meningiomas cause no symptoms at all for years.

When No Symptoms Appear

Small meningiomas tucked into locations away from critical structures can grow slowly for years — sometimes decades — without causing any noticeable problem. These are the tumors discovered incidentally on scans ordered for headaches, minor injuries, or entirely unrelated conditions.

Studies examining incidentally discovered meningiomas show that the majority remain stable or grow very slowly over observation periods of several years. This is precisely why watchful waiting becomes the recommended approach for many small, asymptomatic tumors.

Headaches

Headaches represent the most common symptom when meningiomas do cause problems. They typically develop gradually rather than suddenly. Morning headaches that improve during the day — similar to the pattern seen in other brain tumors — can reflect increased intracranial pressure from the growing mass.

Not every headache associated with a meningioma feels dramatic. Some patients describe a dull, persistent pressure rather than the severe pain popularly associated with brain tumors.

Vision Changes

Meningiomas near the optic nerve, optic chiasm, or sphenoid wing frequently affect vision. Symptoms include gradual blurring of vision in one eye, loss of peripheral vision, double vision, or proptosis — a forward bulging of one eye as the tumor pushes on the orbit from behind.

Vision symptoms from meningioma often develop so gradually that patients don’t notice the change until significant vision loss has already occurred. Regular eye exams sometimes catch these changes before the patient recognizes them.

Weakness or Numbness

Meningiomas pressing on the motor or sensory areas of the brain cause weakness, numbness, or tingling on one side of the body. The location of these symptoms helps neurologists identify which part of the brain is under pressure.

A meningioma near the top of the brain — called a parasagittal or falcine meningioma — often affects leg strength before arm strength, because the motor cortex representation of the legs sits higher on the brain’s surface.

Seizures

Approximately 30% of symptomatic meningioma patients experience seizures. Seizures occur when tumor pressure irritates adjacent brain tissue enough to trigger abnormal electrical activity. First-time seizures in adults always require urgent neurological evaluation.

Personality and Cognitive Changes

Frontal lobe meningiomas can cause personality changes, impulsivity, apathy, or cognitive slowing before any other symptoms appear. Families often notice these changes before the patient acknowledges them.

Hearing Loss or Tinnitus

Meningiomas near the posterior fossa — the back and lower portion of the skull — can press on hearing and balance nerves. Progressive hearing loss in one ear, ringing sounds, or balance problems can all result from tumors in this location.

Endocrine Symptoms

Meningiomas at the base of the skull near the pituitary gland can disrupt hormone production. Vision problems, headaches, and hormonal symptoms — including menstrual irregularities or unexplained weight changes — can result.

Diagnosing Meningioma

MRI With Contrast

MRI is the definitive imaging tool for meningioma diagnosis. On contrast-enhanced MRI, meningiomas produce a characteristic appearance that experienced radiologists recognize reliably.

The tumor typically appears as a well-defined, homogeneously enhancing mass attached to the dura — the outermost meningeal layer. A “dural tail” sign — a thickening of the dura extending away from the tumor margin — appears in many meningiomas and represents a classic imaging feature.

MRI shows the tumor’s size, exact location, relationship to critical brain structures and blood vessels, and any surrounding brain swelling. All of this information shapes treatment planning.

CT Scan

CT scan complements MRI for meningioma evaluation. Meningiomas frequently contain calcium deposits — calcifications — that appear prominently on CT. CT also shows bone involvement more clearly than MRI, which matters when the tumor has grown into the overlying skull or skull base.

Biopsy and Pathology

When imaging findings are characteristic, many neurosurgeons proceed to surgical removal without a pre-operative biopsy — the surgery itself provides tissue for pathological confirmation. For tumors not requiring immediate surgery, stereotactic biopsy provides tissue diagnosis when the imaging picture is unclear.

Pathology confirms the diagnosis, determines grade, and identifies molecular features including NF2 mutation status and other markers that predict recurrence risk and guide surveillance planning.

Treatment Options for Meningioma

Active Surveillance — Watch and Wait

Active surveillance is the recommended approach for small, asymptomatic meningiomas with slow or no measurable growth. This is not passive neglect — it’s a deliberate, evidence-based strategy.

Regular MRI scans — typically every six to twelve months initially, then less frequently if the tumor shows stability — monitor the tumor over time. Treatment begins only if the tumor shows significant growth, develops worrying characteristics on imaging, or begins causing symptoms.

Multiple studies show that a substantial proportion of small meningiomas remain stable for many years without intervention. The risks of surgery or radiation in a patient with no symptoms can genuinely outweigh the risks of careful monitoring.

This was exactly the right recommendation for my aunt’s small, asymptomatic tumor. Understanding the reasoning behind it transformed a frightening recommendation into a sensible one.

Surgery

Surgical removal is the primary treatment for symptomatic meningiomas and for tumors showing significant growth on surveillance imaging. Surgery aims to remove the entire tumor — complete resection offers the best chance of permanent cure for Grade 1 meningiomas.

The extent of resection significantly affects recurrence risk. Complete removal including the involved dura and any affected bone — called a Simpson Grade 1 or 2 resection — carries a much lower recurrence rate than partial removal. However, complete resection isn’t always achievable when tumors sit near critical blood vessels, nerves, or other structures that cannot be sacrificed.

Modern neurosurgical techniques — neuronavigation, intraoperative monitoring of nerve function, and careful preoperative planning with advanced imaging — allow surgeons to achieve more complete removal with better preservation of neurological function than was possible even a decade ago.

Recovery from meningioma surgery follows the general timeline described for craniotomy. Most patients see significant improvement in tumor-related symptoms after successful removal. Neurological deficits that developed gradually from tumor pressure often improve substantially as the pressure resolves.

Stereotactic Radiosurgery

Stereotactic radiosurgery — using systems like Gamma Knife, CyberKnife, or LINAC-based platforms — delivers a precisely focused high dose of radiation to a defined target in a single session or a small number of sessions.

For meningiomas, radiosurgery works best for tumors smaller than approximately 3 centimeters, tumors in surgically challenging locations, residual tumor after incomplete resection, and tumor recurrence after previous surgery.

Radiosurgery controls tumor growth in approximately 90% to 95% of appropriately selected Grade 1 meningiomas over a five-year follow-up period. It doesn’t remove the tumor — the dead tumor tissue often persists on imaging for years after treatment — but it stops growth effectively.

Patients typically experience no significant recovery period after radiosurgery. The session itself takes under an hour. Most return to normal activities the following day.

Conventional Fractionated Radiation Therapy

Standard radiation therapy — delivered in multiple smaller doses over several weeks — treats larger meningiomas unsuitable for radiosurgery, atypical Grade 2 tumors after surgery, and malignant Grade 3 tumors as part of combined treatment.

Fractionated radiation allows higher total doses to be delivered safely by spreading them out over time, reducing the risk to surrounding healthy tissue compared to delivering the same dose in one session.

Medical Treatment — Emerging Options

No FDA-approved drug specifically treats meningioma currently. Medical treatment plays a limited role in standard meningioma care.

Hydroxyurea — an oral chemotherapy drug — has shown modest activity in some recurrent or progressive meningiomas that cannot be managed with surgery or radiation. Results are inconsistent and generally modest.

Several targeted therapies and immunotherapy approaches are currently under investigation in clinical trials. The presence of hormone receptors on many meningiomas has prompted trials of anti-hormonal agents. Molecular profiling has identified potential targets including PDGFR, VEGFR, and SMO that new drugs aim to address.

For patients with recurrent or progressive meningioma that has failed standard approaches, clinical trial participation offers access to these emerging options.

Recurrence After Treatment

Recurrence risk depends primarily on tumor grade and completeness of surgical removal.

Grade 1 meningiomas with complete resection carry approximately 7% to 12% recurrence rates at 10 years — quite favorable. Incomplete resection raises this to approximately 20% to 30% at 10 years, depending on how much tumor remains. Grade 2 atypical meningiomas recur at approximately 30% to 40% at five years even after complete resection. Grade 3 malignant meningiomas carry recurrence rates exceeding 50% despite aggressive treatment.

Regular MRI follow-up continues long after treatment for all meningioma patients — not just those on active surveillance. Recurrence is detectable on imaging before symptoms return, allowing earlier intervention when recurrence does occur.

Living With a Meningioma Diagnosis

A meningioma diagnosis — even a small, benign, asymptomatic one — changes how people experience their own bodies. Knowing a tumor exists creates anxiety that doesn’t disappear just because the tumor requires no immediate treatment.

This psychological dimension is real and deserves acknowledgment. Many meningioma patients describe a persistent background worry between MRI scans — wondering whether this scan will show growth, whether this headache is meaningful, whether the watch-and-wait approach will eventually fail.

Support groups connect patients facing this specific experience. Connecting with others on active surveillance, or others who have undergone surgery or radiosurgery, provides perspective that doctors alone cannot always offer.

Understanding the high rate of stability in well-monitored meningiomas — and the excellent outcomes that treatment achieves when intervention becomes necessary — provides a genuine foundation for managing this anxiety. Knowledge, honestly applied, does help.

Questions to Ask After a Meningioma Diagnosis

• What grade is my meningioma, and what does that mean for its behavior?
• Why is active surveillance the recommendation rather than immediate treatment?
• How often will I need MRI scans, and what growth would trigger a change in approach?
• If treatment becomes necessary, would surgery or radiosurgery be more appropriate for my tumor’s location?
• What symptoms should prompt me to call before the next scheduled scan?
• Does my tumor location explain my specific symptoms?
• Should I seek a second opinion at a specialized meningioma center?

A Final Word

My aunt’s meningioma has remained stable through five years of six-monthly MRI scans. She describes the experience of living with it as something she’s made peace with — not forgotten, but no longer the first thing she thinks about every morning.

Her neurosurgeon told her early on that for her specific tumor, in her specific location, the monitoring approach was genuinely the right choice — not a deferral of the real answer, but the real answer itself.

That clarity helped her. Understanding the reasoning behind her care helped her. Knowing that meningioma is the most common primary brain tumor — that thousands of people live alongside these tumors for decades, that treatment options are effective when needed — helped her.

Information changes the experience of living with a diagnosis. It doesn’t remove uncertainty, but it replaces blank fear with something navigable.

That navigability matters more than most people expect.

For more detailed information about meningioma, visit the
Mayo Clinic Meningioma resource or the
American Cancer Society Brain Tumor Guide.

Disclaimer: This article serves educational and informational purposes only. It does not constitute medical advice or diagnosis. Please consult a qualified neurosurgeon or neuro-oncologist for guidance specific to any individual meningioma diagnosis.